

SARS-CoV-2


SARS-CoV-2 Omicron Variant Pseudovirus Expressing Luciferase

Catalog # U0416


Size 500 uL

Applications


A. G10xA1




B. 7A7



C. 5D6



D. 8C4



Neutralization

A. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone G10xA1 (Cat # MAB23153), and then added into 293T-ACE cells.

B. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 7A7, and then added into 293T-ACE cells.

C. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 5D6, and then added into 293T-ACE cells.

D. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 8C4, and then added into 293T-ACE cells.

Specification

Product Description

SARS-CoV-2 Omicron Variant Pseudovirus Expressing Luciferase can be used to measure neutralizing antibody against SARS-CoV-2.

Materials Required But NOT Supplied

1. 293T-hACE2 cell
2. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
3. ZymeFree™ Enzyme Free Cell Dissociation Reagent, Cat# TCL028-100ML, HIMEDIA
4. DMEM culture medium containing 10% FBS (complete medium)
5. Luciferase Assay System, Cat# E1500, Promega
 - a. Luciferase Assay Substrate (lyophilized)
 - b. Luciferase Assay Buffer
 - c. Luciferase Cell Culture Lysis Reagent, 5X
6. TC-Treated 24 Well Plates, Cat# 3524, Corning
7. OptiPlate™-96, Cat# 6005290, PerkinElmer

Variant

B.1.1.529

Suitable Sample

1. Immunized Serum
2. Infected Serum
3. Neutralizing Antibodies
4. Peptide Inhibitors or Proteins
5. Compounds Targeting Spike Induced Cell Fusion

Sample Volume

10-50 uL (please check sample source)

Detection Method

Luciferase Activity

Technology

[Pseudovirus](#)

Regulatory Status

For research use only (RUO)

Storage Instruction

Store at -80°C
Aliquot to avoid repeated freezing and thawing.

Applications

● Neutralization

- A. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone G10xA1 (Cat # MAB23153), and then added into 293T-ACE cells.
- B. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 7A7, and then added into 293T-ACE cells.
- C. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 5D6, and then added into 293T-ACE cells.
- D. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 8C4, and then added into 293T-ACE cells.